On 2018 Jan 19, Evgeniy Gorbunov commented:

The product described in the paper is not homeopathic. During manufacturing process, the technology of consequential decrease of concentrations was used as it is clearly stated in the Materials and Methods of the paper.

The effect of Subetta on human adipocytes was not assessed in the current study. Animals were assigned randomly to six different groups as it is mentioned in the Materials and Methods. The test samples were supplied encoded. The additional statistical analysis taking into account the adjustment for multiple hypotheses testing confirmed that the effect of Subetta differs from the control effect.

OOO “NPF “MATERIA MEDICA HOLDING” was a sponsor of the experiment as it is mentioned in the Acknowledgments. The test samples were provided by OOO “NPF “MATERIA MEDICA HOLDING” as it is mentioned in the Materials and Methods. Three authors are employees of the company as it is mentioned at the title pages. Thus, all this crucial information was available to readers and it was not concealed.

On 2018 Jan 14, Evgenia V Dueva commented:

In their article Bailbe et al. conclude, that “Subetta and release-active dilutions (RAD) of antibodies to β-subunit insulin receptor treatments are effective to significantly improve glucose homeostasis in GK/Par diabetic rats” and that “chronic oral administration of Subetta and RAD of Abs to β-InsR significantly attenuated fasting hyperglycemia and improved glucose homeostasis in GK/Par rats”. However, they fail to mention that Subetta is made from antibodies diluted beyond Avogadro’s limit (12 consecutive dilutions of 1:100, see Google patents US8535664) and thus contains no active molecules. The authors do not mention homeopathy in their article, but this clearly is a homeopathic drug.

The results obtained by the authors are likely false positives (due to some technical artifact are human biases) considering the very low prior probability of a drug with no active molecules having any specific effect on human adipocytes. The authors have not attempted to use any randomization or blinding techniques to account for such possibilities. More over the data presented in the original paper does not support the abovementioned conclusion, as far as after correct statistical analysis antidiabetic effect of Subetta, can not be distinguished from the effect of water control.

On the ethical side, the authors did not declare conflict of interests, though OOO "NPF "MATERIA MEDICA HOLDING" is a Russian Company that markets a number of drugs which contain active ingredients diluted beyond Avogadro’s limit, including Subetta. Three out of four authors work for this company. Furthermore, Oleg Epstein is CEO of the abovementioned Company.

On 2018 Jan 14, Evgenia V Dueva commented:

In their article Bailbe et al. conclude, that “Subetta and release-active dilutions (RAD) of antibodies to β-subunit insulin receptor treatments are effective to significantly improve glucose homeostasis in GK/Par diabetic rats” and that “chronic oral administration of Subetta and RAD of Abs to β-InsR significantly attenuated fasting hyperglycemia and improved glucose homeostasis in GK/Par rats”. However, they fail to mention that Subetta is made from antibodies diluted beyond Avogadro’s limit (12 consecutive dilutions of 1:100, see Google patents US8535664) and thus contains no active molecules. The authors do not mention homeopathy in their article, but this clearly is a homeopathic drug.

The results obtained by the authors are likely false positives (due to some technical artifact are human biases) considering the very low prior probability of a drug with no active molecules having any specific effect on human adipocytes. The authors have not attempted to use any randomization or blinding techniques to account for such possibilities. More over the data presented in the original paper does not support the abovementioned conclusion, as far as after correct statistical analysis antidiabetic effect of Subetta, can not be distinguished from the effect of water control.

On the ethical side, the authors did not declare conflict of interests, though OOO "NPF "MATERIA MEDICA HOLDING" is a Russian Company that markets a number of drugs which contain active ingredients diluted beyond Avogadro’s limit, including Subetta. Three out of four authors work for this company. Furthermore, Oleg Epstein is CEO of the abovementioned Company.

On 2018 Jan 19, Evgeniy Gorbunov commented:

The product described in the paper is not homeopathic. During manufacturing process, the technology of consequential decrease of concentrations was used as it is clearly stated in the Materials and Methods of the paper.

The effect of Subetta on human adipocytes was not assessed in the current study. Animals were assigned randomly to six different groups as it is mentioned in the Materials and Methods. The test samples were supplied encoded. The additional statistical analysis taking into account the adjustment for multiple hypotheses testing confirmed that the effect of Subetta differs from the control effect.

OOO “NPF “MATERIA MEDICA HOLDING” was a sponsor of the experiment as it is mentioned in the Acknowledgments. The test samples were provided by OOO “NPF “MATERIA MEDICA HOLDING” as it is mentioned in the Materials and Methods. Three authors are employees of the company as it is mentioned at the title pages. Thus, all this crucial information was available to readers and it was not concealed.